Clinical trial
Chemotherapy in Treating Patients With Liver Cancer
NCT00003044 · Matrix Pharmaceutical, Industry · Unknown status
Key facts
| NCT number | NCT00003044 |
|---|---|
| Title | Chemotherapy in Treating Patients With Liver Cancer |
| Official title | A Two-Stage Phase II Safety and Efficacy Study of IntraDose (Cisplatin/Epinephrine) Injectable Gel (MPI 5010) Administered to Patients With Unresectable Primary Hepatocellular Carcinoma |
| Lead sponsor | Matrix Pharmaceutical, Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Liver Cancer |
| Intervention type | Drug |
| Interventions | cisplatin-e therapeutic implant |
| Enrollment | 55 |
| Start date | Sep 1, 1996 |
| First posted | Aug 12, 2004 |
| Last update posted | Dec 19, 2013 |
| Countries | Hong Kong, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: